Skip to main content
Fig. 7 | BMC Urology

Fig. 7

From: Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis

Fig. 7

Traditional meta-analysis of comparisons that were not included in the network meta-analysis. Abbreviations: BSC: Best support care; GC: Gemcitabine plus carboplatin; GEM: Gemcitabine; GEMOX: Gemcitabine plus oxaliplatin; MCAVI: Methotrexate plus carboplatin plus vinblastine; PPV: Personalized peptide vaccination; VC: Vinflunine plus Carboplatin; VG: Vinflunine plus Gemcitabine; VIN: Vinflunine

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us